GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Tangible Book per Share

Anixa Biosciences (Anixa Biosciences) Tangible Book per Share : $0.74 (As of Apr. 2024)


View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Anixa Biosciences's tangible book value per share for the quarter that ended in Apr. 2024 was $0.74.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Anixa Biosciences Tangible Book per Share Historical Data

The historical data trend for Anixa Biosciences's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences Tangible Book per Share Chart

Anixa Biosciences Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Tangible Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.36 1.18 0.94 0.78

Anixa Biosciences Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 0.82 0.78 0.78 0.74

Competitive Comparison of Anixa Biosciences's Tangible Book per Share

For the Biotechnology subindustry, Anixa Biosciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Price-to-Tangible-Book falls into.



Anixa Biosciences Tangible Book per Share Calculation

Anixa Biosciences's Tangible Book Value Per Share for the fiscal year that ended in Oct. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(24.337-0-0)/31.1452
=0.78

Anixa Biosciences's Tangible Book Value Per Share for the quarter that ended in Apr. 2024 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(23.623-0-0)/32.0065
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Anixa Biosciences  (NAS:ANIX) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Anixa Biosciences Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Anixa Biosciences (Anixa Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Executives
Amit Kumar director, officer: Chief Executive Officer C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani officer: COO & CFO 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Titterton Lewis H Jr director 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Emily Gottschalk director 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan director
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams director C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox director 929 NOWITA PLACE, VENICE CA 90291
Andrea Belz director 1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender officer: Chief Operating Officer 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman officer: President and CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop officer: Sr. Vice President-Engineering C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson director 20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams director C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747